{"entity": "publication", "iuid": "4fe382cea19245baa34b3e4c81f76cc6", "timestamp": "2026-09-28T11:17:38.720Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/4fe382cea19245baa34b3e4c81f76cc6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/4fe382cea19245baa34b3e4c81f76cc6"}}, "title": "What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.", "authors": [{"family": "Claesson-Welsh", "given": "Lena", "initials": "L", "orcid": "0000-0003-4275-2000", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6b07fbf00dad4ac8a4a53402888d55ef.json"}}], "type": "journal article", "published": "2019-08-00", "journal": {"title": "EMBO Mol Med", "issn": "1757-4684", "volume": "11", "issue": "8", "pages": "e10892", "issn-l": "1757-4676"}, "abstract": "In this issue of EMBO Molecular Medicine, Uribesalgo and coworkers show that high Apelin expression correlates with poor survival in advanced breast (MMTV-NeuT) and lung (KRASG12D ) murine tumor models as well as in breast and lung cancer in humans. Combining Apelin inhibition (genetically or using an inactive Apelin agonist) with anti-angiogenic therapy using different small molecular weight kinase inhibitors (sunitinib, axitinib) led to marked delay in breast cancer growth in mice. The vasculature in Apelin-targeted cancer showed normalized features including improved perfusion and reduced leakage. These important data provide a strong incentive to target Apelin in human cancer treatment.", "doi": "10.15252/emmm.201910892", "pmid": "31318171", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6685083"}], "notes": [], "created": "2026-09-23T13:10:41.294Z", "modified": "2026-09-23T13:10:41.333Z"}